Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores.
Clinical takeawayConsider using ESC Cardio-Oncology classification or CARDIOSOR score to stratify cardiovascular risk in patients with uHCC before initiating atezolizumab/bevacizumab therapy. For high-risk patients, weigh bevacizumab-free alternatives as a comparator.
What it foundPatients classified as very high-risk by ESC Cardio-Oncology classification (specific thresholds not provided in abstract) or high-risk by CARDIOSOR score (specific thresholds not provided in abstract) had significantly increased risk of tMACE (3.7%) and eMACE (5.6%).
ContextThis study provides evidence for cardiovascular risk stratification in uHCC patients on atezolizumab/bevacizumab, addressing a gap in cirrhosis-specific risk assessment.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Stefanini B … ARTE Study Group · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗